Jennifer Brown, MD, PhD, discusses final stage 2 results of the CLL11 trial at the 2013 American Society of Hematology (ASH) Meeting.
Clinical Pearls
Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses final stage 2 results of the CLL11 trial at the 2013 American Society of Hematology (ASH) Meeting.
The CLL11 study provided the basis for the approval of GA101 (obinutuzumab)
GA101 has a different mechanism than rituximab or ofatumumab in that it confers increased direct cell death
GA101 + chlorambucil compared with chlorambucil alone now has demonstrated a statistically significant improvement in overall survival
In the direct comparison, GA101 + chlorambucil demonstrated an improvement in progression-free survival compared with rituximab + chlorambucil (27 months vs 16 months)
GA101 + chlorambucil also has demonstrated a higher complete remission rate and MRD negativity rate
